Sanofi-Aventis Purchases $42.4 Million Worth of Regeneron Pharmaceuticals Inc (REGN)’s Stock

On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S. Securities and Exchange Commission, declaring several purchases of the company’s stock. On. Jan. 27th the insider acquired – through several different transactions – more than 74,000 shares. On the following day, the pharmaceutical group bought stock yet again; this time, more than 83,000 shares. He paid prices ranging from $270.18 to $279.73 per share, inclusive. After the reported transactions –on which Sanofi spent roughly $42.4 million, the shareholder owns 15.97 million shares of the company worth more than $4.5 billion.

Ken Griffin with computers

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is, as its name clearly indicates, a $28 billion market cap integrated biopharmaceutical company that discovers, develops and manufactures medicines for the treatment of serious medical conditions. The company holds a promising product pipeline and a leading monoclonal antibody research and development platform. Trading at 41.8 times its earnings, a 30% discount versus the industry average valuation, while offering industry leading margins and returns –more than triple the industry mean values, this stock looks like a catch. In fact, most analysts consider this company´s stock to be a buy or strong buy case, and expect it to deliver above average annual EPS growth rates over the next five years (31.5% in average).

Sanofi, a healthcare company more than four times bigger than Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in terms of market cap, continues to invest in this pharmaceutical company and many analysts consider that an acquisition could occur somewhere down the road. If this were to happen, other stockholders could result highly benefited.

Besides analysts and Sanofi, there are several hedge funds that also seem to like Regeneron Pharmaceuticals Inc (NASDAQ:REGN). In its last 13F form, Samuel Isaly´s Orbimed Advisors –the largest “hedgie” bull- declared an increase of 46% in its position in the stock. The fund now holds 513,100 shares, valued at approximately $ 1.46 billion. This position comprised 2.86% of Orbimed´s Q3 equity portfolio.

Second in terms of bullish sentiment is Donald Chiboucis‘ Columbus Circle Investors, which also augmented its bets on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) over the last reported quarter. The fund upped its stakes by 6%, and owned more than 451,500 shares at the end of Q3, which accounted for 1% of its total equity holdings.

Finally, third in line is Ken Griffin’s Citadel Investment Group. The fund boosted its involvement in the company by 1488% in its last reported quarter. Griffin’s fund now owns 383,572 shares. Other prominent funds that also incremented their bets on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are Jim Simons’ Renaissance Technologies and Adage Capital Management.

 

Disclosure: Javier Hasse holds no position in any stocks mentioned

Recommended Reading:

General Electric Company (GE) Continues to Witness Strong Insider Activity

Irving Kahn and a Board Director Bullish About Old Republic International Corporation (ORI)

Michael Novogratz and Insiders Are Bullish About These 4 Stocks

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!